As shown herein, a bi-specific CD19-bridging protein containing an anti-Her2 and an anti-EGFR scFv killed tumor cell expressing one or the other antigen, while showing exceptional potency when both antigens were present. This evidence concerns the gene CD19 and neoplasm.